Rosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offering legal representation for affected investors.

Rosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.

Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. The firm is seeking shareholders who currently own TMDX stock to join the investigation.

TransMedics stock fell 8% after Q2 earnings showed 21% sales growth but adjusted net income dropped more than 50% due to reinvestment in new kidney organ care systems and manufacturing. Despite the decline, the analyst remains bullish on the stock, citing upcoming clinical trials for heart and lung systems, a new kidney OCS in development, and European expansion opportunities.

Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.

TransMedics Group is building a vertically integrated logistics network for organ transplantation through its Organ Care System (OCS) and National OCS Program, which extends organ viability during transport. Despite a 45% stock decline following Q1 2026 earnings miss due to margin compression from expansion spending, the company's 21% YoY revenue growth and potential kidney program expansion into Europe position it as a category-defining infrastructure provider in transplant medicine over the next decade.

The article recommends three growth stocks experiencing temporary pullbacks: SoFi Technologies (down 34% YTD despite strong financial results), Robinhood Markets (facing crypto revenue headwinds but diversifying revenue streams), and TransMedics Group (expanding internationally with rising expenses but solid business fundamentals). All three are positioned as long-term opportunities for investors comfortable with volatility.

TransMedics Group director Thomas J. Gunderson sold 9,624 shares worth approximately $722,000 following the exercise of vested stock options to cover exercise costs and tax obligations. The sale reflects routine portfolio management rather than a loss of confidence. Despite a 45% stock decline over the past year, TransMedics reported strong Q1 revenue of $173.9 million (up 21% YoY) and maintained full-year guidance of $727-$757 million, suggesting the stock decline may have been an overreaction.

The article recommends three underappreciated growth stocks: Credo Technology (AI data center connectivity), Cellebrite (law enforcement digital evidence software), and TransMedics (organ transplant preservation technology). Each company is positioned in large, expanding markets with limited competition and strong fundamentals.

Short sellers are heavily targeting 10 stocks with short interest exceeding 40% of float. Choice Hotels and Avis Budget lead with over 50% short interest, while Lucid Group, Hertz Global, and crypto/semiconductor plays like Marathon Digital and CleanSpark also face significant bearish positioning. Traders are watching for potential squeeze opportunities if positive catalysts emerge.

TransMedics Group has surged 104% over the past year as it dominates the organ transplant industry with its innovative Organ Care System and National OCS Program. Despite trading at a premium 56x forward earnings and facing significant short interest (25% of float), the company's strong growth (32% quarterly sales growth), expanding moat through vertical integration, and international expansion opportunities suggest the valuation may be justified for long-term investors.

Joby Aviation's stock has fallen 25% year-to-date and is trading 50% below 2025 highs at $9.56. While the lower price may seem attractive, the company's $9.4 billion market cap is still higher than established competitors like American Airlines, Lyft, and TransMedics despite having no commercial operations yet. The analyst recommends caution, noting the stock appears priced for perfection given Joby's unproven eVTOL air taxi business model and pending FAA certification.